“Today, Gerresheimer is a profitable growth company — and I believe that our best years lie ahead of us,” said Dietmar Siemssen, CEO of Gerresheimer AG: “As a provider of systems and solutions, we are a key strategic partner of the pharma and biotech industries and are growing in all areas. In particular, medical devices for biopharmaceuticals, including the new GLP-1 applications, are currently offering us excellent growth opportunities.” The company is also aiming for double-digit growth rates in revenues and adjusted EBITDA in the coming years.
Dividend of EUR 1.25 for strong financial year 2022
The Annual General Meeting approved a dividend of EUR 1.25 per share for the financial year 2022. This corresponds to a payout ratio of around 27 % of adjusted net income, which is once again at the upper end of the 20 % to 30 % range defined by Gerresheimer. The dividend is to be paid out on June 12, 2023.
In the financial year 2022, Gerresheimer recorded a strong performance in a challenging economic environment, generating revenues of EUR 1.82 billion and adjusted EBITDA of EUR 354 million.
High approval rates
With 81.27% of the share capital present, the Annual General Meeting adopted all resolutions by a large majority. As a result, the actions of the Management Board and Supervisory Board were approved by a large majority. Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was elected as auditor for the financial year 2023.
The detailed voting results for the items on the Annual General Meeting’s agenda are available at:
https://www.gerresheimer.com/en/company/investor-relations/annual-general-meeting
The speech by the Chief Executive Officer at the Annual General Meeting is available at:
https://www.gerresheimer.com/en/company/investor-relations/annual-general-meeting
The Annual Report is available at:
https://www.gerresheimer.com/en/company/investor-relations/reports
Contact Gerresheimer AG
Press
Jutta Lorberg
Head of Corporate Communication
T +49 152 900 345 46
jutta.lorberg-remove@remove-gerresheimer.com
Investor Relations
Christian Lösse
Senior Manager Investor Relations
Investor Relations
T +49 211 6181-314
christian.loesse-remove@remove-gerresheimer.com
About Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2022 of EUR 1.82bn. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
www.gerresheimer.com/
